Da multiple myelomer kun forekommer hos få patienter, blev Revlimid den 12. december 2003 udpe - get som "lægemiddel til sjældne sygdomme".
Because the number of patients with multiple myeloma is low, the disease is considered ‘ rare’, and Revlimid was designated an ‘ orphan medicine ’ (a medicine used in rare diseases) on 12 December 2003.